Stock·NASDAQ·Healthcare
Natera, Inc. (NTRA)
- Market cap
- $58.35B
- Dividend yield
- 0.00%
- Street target
- $370.00median of 23 analysts
- 52-week range
- $178.01 $437.41
The short version
Where NTRA stands today, in four lines, and what CleaRank Financial AI makes of it.
NTRA at a glance
Natera, Inc. (NTRA): Buy, 78/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($358.04 and $257.48).
- Earnings NTRA beat estimates in 3 of its last 7 quarters, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $418.3M and made no open-market purchases over the last 18 months.
Figures as of October 16, 2026.
CleaRank Financial AI
Natera, Inc. (NTRA) is trading at $391.03, above its 50-day and 200-day moving averages ($358.04 and $257.48), indicating a generally positive short-to-medium term trend.
The company's revenue growth is projected to be strong, with current year estimates at +26.00% and next year at +21.00%. Analyst sentiment is largely positive, with a consensus rating of 'Buy' and a median price target of $370.00, suggesting a slight downside from current levels. Despite the positive outlook on growth and analyst coverage, Natera faces significant challenges. The company is currently loss-making, with a negative EPS of -1.35 and a negative profit margin of -7.11%. Also, insider activity reveals heavy net selling, with over $418 million in sales and no reported purchases, signaling potential caution from management. The stock's price-to-sales ratio of 21.02 is considerably higher than the sector median of 3.4, indicating a premium valuation that may be difficult to sustain without continued rapid growth.
Only on CleaRank
Figures we compute ourselves from NTRA's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $391.03 is 9.2% above the 50-day simple moving average of $358.04.Price above its 200-day average ›
The price is 51.9% above the 200-day simple moving average of $257.48.50-day average above the 200-day ›
The 50-day average ($358.04) is 39.1% above the 200-day average ($257.48), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 82% of its 52-week range, between $178.01 and $437.41.
NTRA share price
Pick a period: each tab shows how far NTRA has moved over it, to the last close.
Today's trading
Where NTRA sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
0/3P/S below the sector median ›
The price-to-sales ratio of 21.02 is 518.2% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $-192.3M on revenue of $2.7B, a net margin of -7.1%.Beat estimates in most recent reports ›
NTRA beat the EPS estimate in 3 of its last 7 reports.
Key statistics
The headline figures for NTRA.
As of October 16, 2026, NTRA trades at $391.03, with a market value of $58.35B and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of NTRA's valuation, growth and risks.
Natera, Inc. (NTRA) exhibits a high price-to-sales ratio of 21.02, significantly above the sector median of 3.4, indicating that investors are paying a premium for its revenue.
This premium valuation is not supported by current profitability, as the company reports a negative EPS of -1.35 and a net profit margin of -7.11%. The return on equity is also negative at -12.54%, further highlighting the company's unprofitability. Despite the valuation concerns and lack of current profits, Natera is experiencing strong revenue growth, reported at 37.7% and projected to continue at 26.00% for the current year and 21.00% for the next. The company maintains a low debt-to-equity ratio of 0.13, suggesting a healthy balance sheet and limited financial risk from leverage. This growth trajectory, coupled with a strong balance sheet, appears to be the primary driver for the current premium valuation and positive analyst sentiment.
NTRA against the Healthcare sector
How NTRA compares with the median Healthcare stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, NTRA trades at 21.02x, far above the sector average of 3.40x.
Return vs XLV: Since May 5, 2025, NTRA has gained 157.2% against a gain of 28.3% for XLV.
Performance against XLV
NTRA and the Healthcare sector fund over the same days.
Revenue and earnings
How much NTRA sells, and how much of it becomes profit.
Revenue growth: Revenue grew 35.9% in FY2025 to $2.3B, from $1.7B a year earlier.
Profit margin: The net margin was -9.0% in FY2025, up from -11.2% the year before.
Profitable: NTRA lost $208M in FY2025.
Earnings reality check
Did NTRA beat what analysts expected, and how did the stock react?
Earnings record: NTRA beat the analyst estimate in 3 of the last 7 quarters.
Market reaction: The stock fell in the first session after 1 of those 3 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 6, 2026after close | -$0.53 | -$0.47 | +11.32% | +21.37% | +17.11% |
| May 7, 2026after close | -$0.55 | -$0.60 | -9.09% | -11.64% | -10.42% |
| Nov 6, 2025after close | -$0.35 | -$0.64 | -82.86% | +0.55% | +1.10% |
| Aug 7, 2025after close | -$0.59 | -$0.74 | -25.42% | +7.70% | +12.31% |
| May 8, 2025after close | -$0.66 | -$0.50 | +24.24% | -6.53% | -8.10% |
| Feb 27, 2025after close | -$0.35 | -$0.41 | -17.14% | -0.65% | -9.65% |
| Nov 12, 2024after close | -$0.59 | -$0.26 | +55.93% | +19.13% | +19.97% |
As of October 16, 2026, NTRA has beaten the analyst EPS estimate in 3 of its last 7 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on August 6, 2026, came in 11.32% above the estimate and the stock moved +21.37% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 53.6, in neutral territory.RSI above 50 ›
An RSI of 53.6 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of NTRA
The score, the reasoning behind it, and what could move the price next.
Natera, Inc. (NTRA) is currently trading at $391.03, with its 14-day RSI at 53.6, indicating neutral momentum.
The stock is trading above its 50-day SMA of $358.04 and its 200-day SMA of $257.48, suggesting a bullish trend over the longer term. However, it is currently trading below its 20-day EMA of $391.68, which could signal near-term weakness or consolidation. Key support levels are indicated by the 50-day SMA at $358.04 and the 200-day SMA at $257.48, while resistance may be found near recent highs.
Strong Revenue Growth Projections ›
Natera is projected to achieve 26.00% revenue growth in the current year and 21.00% in the next, indicating significant market adoption and expansion potential.
Source: Wall Street EstimatesPositive Analyst Sentiment ›
A 'Buy' consensus from 23 analysts, with a median price target of $370.00, suggests Wall Street believes the stock has potential despite current challenges.
Source: Wall Street Summary
Premium Valuation ›
A price-to-sales ratio of 21.02 significantly exceeds the sector median of 3.4, suggesting the stock may be overvalued and vulnerable to a correction.
Source: Company FundamentalsRecent EPS Beat ›
The latest earnings report on August 6, 2026, showed an EPS beat of 11.32%, leading to a 21.37% stock price increase, demonstrating the market's sensitivity to earnings performance.
Source: Earnings Analysis
- The stock's current trading above its 50-day and 200-day moving averages ($358.04 and $257.48) suggests a bullish trend, but the price is below its 20-day EMA, indicating potential near-term consolidation or weakness.
- Given the high valuation (P/S of 21.02 vs sector median of 3.4) and current unprofitability, investors should consider position sizing carefully and monitor revenue growth closely against analyst expectations.
Technical indicators
Momentum and trend for NTRA, from its daily closes.
As of October 16, 2026, with NTRA at $391.03, its 14-day RSI is 53.6 (neutral territory), its 50-day simple moving average is $358.04 and its 200-day is $257.48.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What NTRA moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, NTRA's 1-year correlation of daily returns is +0.44 with S&P 500 (SPY), +0.43 with Nasdaq 100 (QQQ), +0.20 with Bitcoin (BTC) and +0.14 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
21 of 23 analysts rate it a buy or strong buy, 2 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $370.00 is 5.4% below the price.More buy ratings than three months ago ›
21 of 23 rate it a buy now, against 19 of 22 three months ago.
NTRA Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Maintains | Overweight |
| Oct 6, 2026 | Citigroup | Maintains | Buy |
| Oct 1, 2026 | Guggenheim | Maintains | Buy |
| Sep 25, 2026 | RBC Capital | Maintains | Outperform |
| Sep 9, 2026 | UBS | Maintains | Buy |
| Sep 8, 2026 | Rothschild & Co | Initiates | Buy |
As of October 16, 2026, 23 Wall Street analysts cover NTRA: 21 rate it a buy or strong buy, 2 a hold and 0 a sell or strong sell. Their 12-month price targets range from $280.00 to $490.00, with a median of $370.00, 5.4% below the price of $391.03.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
NTRA trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from NTRA's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much NTRA tends to move, against the market and on its own.
The long record
NTRA's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 2.55% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 75.8%, from January 2021 to May 2022, regained by August 2024.Most 1-year holds ended higher ›
82% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $390,724, against $42,525 in the S&P 500 (SPY).
NTRA Drawdowns & Recovery
As of October 16, 2026, NTRA's worst peak-to-trough fall over the last 10 years with dividends reinvested was -75.8% (January 2021 to May 2022); it regained that peak by August 2024, 27 months after the low, and 82% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into NTRA in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: NTRA beat the S&P 500 over this period: $390,724 against $42,525.
A $10,000 investment in NTRA in October 2016 would be worth about $390,724 today with dividends reinvested, compared with about $42,525 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to NTRA, and which have not.
Strongest month, August: an average of +21.94%, up in 10 of 10 years.
Weakest month, March: an average of -2.75%, up in 4 of 10 years.
This month, October: has averaged +0.36%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, NTRA's strongest calendar month has been August (average +21.94%, up in 10 of 10 years) and its weakest March (average -2.75%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in NTRA, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in NTRA today could grow to about $30,605 by 2036 in the base case, with a 90th-percentile outcome near $232,189 and a 10th-percentile outcome around $4,034. Projections are statistical simulations, not guarantees.
NTRA Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $612 for NTRA by 2030 in the base case, from $391 today (1.6x over 4 years). The 10th-percentile path ends near $170. These are outcomes of a Monte Carlo simulation run on NTRA's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $230 | $437 | $830 | |
| 2028 | $198 | $489 | $1,210 | |
| 2029 | $180 | $547 | $1,659 | |
| 2030 | $170 | $612 | $2,204 | |
| 2031 | $163 | $684 | $2,867 |
Method: a lognormal simulation of NTRA's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. NTRA is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation.
Insider trading
What the people running the company have bought and sold.
NTRA insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought NTRA shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 16, 2026, NTRA insiders reported 180 open-market sales worth $418.3M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 15, 2026 | Matthew Rabinowitz
Officer and Director
|
Sell | 102.0K | $34.8M |
| Sep 11, 2026 | Matthew Rabinowitz
Officer and Director
|
Sell | 50.0K | $16.4M |
| Sep 2, 2026 | Solomon Moshkevich
Officer
|
Sell | 18.2K | $5.9M |
| Sep 1, 2026 | Steven Leonard Chapman
Chief Executive Officer
|
Sell | 1.7K | $545.0K |
| Aug 10, 2026 | John Fesko
President
|
Sell | 6.5K | $2.1M |
| Aug 10, 2026 | Jonathan Sheena
Director
|
Sell | 6.0K | $2.0M |
| Aug 7, 2026 | Jonathan Sheena
Director
|
Sell | 9.2K | $2.9M |
| Aug 7, 2026 | Matthew Rabinowitz
Officer and Director
|
Sell | 2.0K | $641.8K |
| Aug 6, 2026 | John Fesko
President
|
Grant | 20.0K | - |
| Aug 4, 2026 | Michael Burkes Brophy
Chief Financial Officer
|
Sell | 795 | $216.0K |
| Aug 3, 2026 | Solomon Moshkevich
Officer
|
Sell | 3.4K | $905.6K |
| Aug 3, 2026 | Steven Leonard Chapman
Chief Executive Officer
|
Sell | 3.1K | $819.4K |
| Aug 3, 2026 | Matthew Rabinowitz
Officer and Director
|
Sell | 731 | $195.9K |
| Aug 3, 2026 | Daniel A Rabinowitz
Officer
|
Sell | 334 | $89.5K |
| Aug 3, 2026 | John Fesko
President
|
Sell | 295 | $79.1K |
| Aug 3, 2026 | Jonathan Sheena
Director
|
Sell | 109 | $29.2K |
| Jul 29, 2026 | Michael Burkes Brophy
Chief Financial Officer
|
Sell | 5.1K | $1.3M |
| Jul 28, 2026 | Steven Leonard Chapman
Chief Executive Officer
|
Sell | 5.8K | $1.5M |
| Jul 28, 2026 | Solomon Moshkevich
Officer
|
Sell | 2.2K | $569.0K |
| Jul 28, 2026 | Daniel A Rabinowitz
Officer
|
Sell | 1.9K | $485.1K |
| Jul 28, 2026 | John Fesko
President
|
Sell | 1.7K | $440.2K |
| Jul 28, 2026 | Jonathan Sheena
Director
|
Sell | 479 | $123.5K |
| Jul 27, 2026 | Matthew Rabinowitz
Officer and Director
|
Sell | 1.7K | $447.5K |
| Jul 15, 2026 | Jonathan Sheena
Director
|
Sell | 1.5K | $410.8K |
| Jul 15, 2026 | Rowan Emma Chapman
Director
|
Sell | 135 | $37.1K |
| Jul 13, 2026 | Jonathan Sheena
Director
|
Sell | 3.2K | $836.9K |
| Jul 6, 2026 | Matthew Rabinowitz
Officer and Director
|
Sell | 1.0K | $280.0K |
| Jul 1, 2026 | Daniel A Rabinowitz
Officer
|
Sell | 16.8K | $4.6M |
| Jul 1, 2026 | Solomon Moshkevich
Officer
|
Sell | 3.0K | $818.7K |
| Jun 26, 2026 | Roy D Baynes
Director
|
Grant | 1.6K | - |
| Jun 26, 2026 | Monica Bertagnolli
Director
|
Grant | 1.6K | - |
| Jun 26, 2026 | Roelof Frederick Botha
Director
|
Grant | 1.7K | - |
| Jun 26, 2026 | Rowan Emma Chapman
Director
|
Grant | 1.7K | - |
| Jun 26, 2026 | Thomas J Jr., M.d., Lynch
Director
|
Grant | 1.9K | - |
| Jun 26, 2026 | Gail Boxer Marcus
Director
|
Grant | 1.7K | - |
| Jun 26, 2026 | Herman Rosenman
Director
|
Grant | 1.7K | - |
| Jun 26, 2026 | Eric Rubin
Director
|
Grant | 75 | - |
| Jun 24, 2026 | Daniel A Rabinowitz
Officer
|
Sell | 33.6K | $8.5M |
| Jun 24, 2026 | Herman Rosenman
Director
|
Sell | 16.5K | $4.1M |
| Jun 17, 2026 | Jonathan Sheena
Director
|
Sell | 1.5K | $329.8K |
| Jun 16, 2026 | Rowan Emma Chapman
Director
|
Sell | 3.0K | $642.5K |
| Jun 15, 2026 | Matthew Rabinowitz
Officer and Director
|
Sell | 100.0K | $21.4M |
| Jun 15, 2026 | Jonathan Sheena
Director
|
Sell | 3.2K | $665.1K |
| Jun 5, 2026 | Gail Boxer Marcus
Director
|
Sell | 11.0K | $2.4M |
| Jun 5, 2026 | Gail Boxer Marcus
Director
|
Option | 11.0K | $251.1K |
| Jun 4, 2026 | Steven Leonard Chapman
Chief Executive Officer
|
Sell | 41.1K | $9.1M |
| Jun 1, 2026 | Roelof Frederick Botha
Director
|
Sell | 78.0K | $17.2M |
| Jun 1, 2026 | Solomon Moshkevich
Officer
|
Sell | 3.0K | $655.3K |
| May 29, 2026 | Eric Rubin
Director
|
Grant | 2.1K | - |
| May 26, 2026 | Solomon Moshkevich
Officer
|
Sell | 1.7K | $335.1K |
| May 26, 2026 | John Fesko
President
|
Sell | 1.4K | $291.7K |
| May 13, 2026 | Jonathan Sheena
Director
|
Sell | 4.7K | $959.5K |
| May 5, 2026 | Matthew Rabinowitz
Officer and Director
|
Sell | 7.7K | $1.6M |
| May 5, 2026 | Matthew Rabinowitz
Officer and Director
|
Grant | 2.4K | - |
| May 4, 2026 | Michael Burkes Brophy
Chief Financial Officer
|
Sell | 795 | $166.0K |
| May 1, 2026 | Solomon Moshkevich
Officer
|
Sell | 3.4K | $693.6K |
| May 1, 2026 | Steven Leonard Chapman
Chief Executive Officer
|
Sell | 902 | $186.0K |
| May 1, 2026 | Daniel A Rabinowitz
Officer
|
Sell | 330 | $68.0K |
| May 1, 2026 | John Fesko
President
|
Sell | 291 | $60.0K |
| May 1, 2026 | Jonathan Sheena
Director
|
Sell | 107 | $22.1K |
| Apr 29, 2026 | Michael Burkes Brophy
Chief Financial Officer
|
Sell | 5.1K | $1.0M |
| Apr 29, 2026 | Jonathan Sheena
Director
|
Sell | 3.5K | $699.7K |
| Apr 27, 2026 | Steven Leonard Chapman
Chief Executive Officer
|
Sell | 5.8K | $1.2M |
| Apr 27, 2026 | Solomon Moshkevich
Officer
|
Sell | 2.2K | $445.3K |
| Apr 27, 2026 | Daniel A Rabinowitz
Officer
|
Sell | 1.9K | $379.8K |
| Apr 27, 2026 | John Fesko
President
|
Sell | 1.7K | $344.5K |
| Apr 24, 2026 | Roy D Baynes
Director
|
Grant | 83 | - |
| Apr 24, 2026 | Monica Bertagnolli
Director
|
Grant | 83 | - |
| Apr 24, 2026 | Roelof Frederick Botha
Director
|
Grant | 354 | - |
| Apr 24, 2026 | Rowan E Chapman
Director
|
Grant | 336 | - |
| Apr 24, 2026 | Gail Boxer Marcus
Director
|
Grant | 330 | - |
| Apr 24, 2026 | Herman Rosenman
Director
|
Grant | 339 | - |
| Apr 24, 2026 | Eric Rubin
Director
|
Grant | 5 | - |
| Apr 24, 2026 | Brinkley Ruth Williams
Director
|
Grant | 86 | - |
| Apr 17, 2026 | Jonathan Sheena
Director
|
Sell | 1.5K | $299.4K |
| Apr 6, 2026 | Matthew Rabinowitz
Officer and Director
|
Option | 58.3K | $559.0K |
| Apr 1, 2026 | Daniel A Rabinowitz
Officer
|
Sell | 8.4K | $1.7M |
| Apr 1, 2026 | Solomon Moshkevich
Officer
|
Sell | 3.0K | $606.9K |
| Mar 31, 2026 | Matthew Rabinowitz
Officer and Director
|
Option | 41.7K | $400.0K |
| Mar 20, 2026 | Jonathan Sheena
Director
|
Sell | 4.6K | $908.3K |
| Mar 16, 2026 | Matthew Rabinowitz
Officer and Director
|
Sell | 200.0K | $38.3M |
| Mar 16, 2026 | Matthew Rabinowitz
Officer and Director
|
Option | 200.0K | $1.9M |
| Mar 13, 2026 | Rowan E Chapman
Director
|
Sell | 122 | $23.3K |
| Mar 10, 2026 | Steven Leonard Chapman
Chief Executive Officer
|
Sell | 5.6K | $1.1M |
| Mar 10, 2026 | Daniel A Rabinowitz
Officer
|
Sell | 1.7K | $356.2K |
| Mar 10, 2026 | Solomon Moshkevich
Officer
|
Sell | 915 | $186.8K |
| Mar 10, 2026 | Michael Burkes Brophy
Chief Financial Officer
|
Sell | 785 | $160.2K |
| Mar 10, 2026 | Jonathan Sheena
Director
|
Sell | 127 | $25.9K |
| Mar 9, 2026 | Michael Burkes Brophy
Chief Financial Officer
|
Grant | 2.0K | - |
| Mar 9, 2026 | Steven Leonard Chapman
Chief Executive Officer
|
Grant | 5.6K | - |
| Mar 9, 2026 | Solomon Moshkevich
Officer
|
Grant | 1.8K | - |
| Mar 9, 2026 | Daniel A Rabinowitz
Officer
|
Grant | 1.7K | - |
| Mar 9, 2026 | Jonathan Sheena
Director
|
Grant | 258 | - |
| Mar 6, 2026 | Daniel A Rabinowitz
Officer
|
Sell | 8.4K | $1.6M |
| Mar 6, 2026 | Daniel A Rabinowitz
Officer
|
Option | 5.6K | $110.2K |
| Mar 2, 2026 | Steven Leonard Chapman
Chief Executive Officer
|
Sell | 4.0K | $790.1K |
| Mar 2, 2026 | Jonathan Sheena
Director
|
Sell | 3.1K | $614.7K |
| Mar 2, 2026 | Solomon Moshkevich
Officer
|
Sell | 3.0K | $599.5K |
| Mar 2, 2026 | Solomon Moshkevich
Officer
|
Option | 5.1K | $49.1K |
| Feb 27, 2026 | Michael Burkes Brophy
Chief Financial Officer
|
Grant | 10.1K | - |
| Feb 27, 2026 | Steven Leonard Chapman
Chief Executive Officer
|
Grant | 37.4K | - |
| Feb 27, 2026 | John Fesko
President
|
Grant | 10.1K | - |
| Feb 27, 2026 | Solomon Moshkevich
Officer
|
Grant | 10.1K | - |
| Feb 27, 2026 | Daniel A Rabinowitz
Officer
|
Grant | 12.3K | - |
| Feb 27, 2026 | Matthew Rabinowitz
Officer and Director
|
Grant | 29.9K | - |
| Feb 27, 2026 | Jonathan Sheena
Director
|
Grant | 2.1K | - |
| Feb 3, 2026 | Steven Leonard Chapman
Chief Executive Officer
|
Sell | 90.0K | $20.8M |
| Feb 3, 2026 | Michael Burkes Brophy
Chief Financial Officer
|
Sell | 6.9K | $1.6M |
| Feb 3, 2026 | Solomon Moshkevich
Officer
|
Sell | 4.6K | $1.1M |
| Feb 3, 2026 | John Fesko
President
|
Sell | 3.6K | $830.3K |
| Feb 3, 2026 | Daniel A Rabinowitz
Officer
|
Sell | 1.3K | $307.8K |
| Feb 3, 2026 | Jonathan Sheena
Director
|
Sell | 435 | $100.4K |
| Jan 30, 2026 | Roy D Baynes
Director
|
Grant | 70 | - |
| Jan 30, 2026 | Monica Bertagnolli
Director
|
Grant | 70 | - |
| Jan 30, 2026 | Roelof Frederick Botha
Director
|
Grant | 112 | - |
| Jan 30, 2026 | Rowan E Chapman
Director
|
Grant | 97 | - |
| Jan 30, 2026 | John Fesko
President
|
Grant | 6.1K | - |
| Jan 30, 2026 | Gail Boxer Marcus
Director
|
Grant | 91 | - |
| Jan 30, 2026 | Herman Rosenman
Director
|
Grant | 99 | - |
| Jan 30, 2026 | Brinkley Ruth Williams
Director
|
Grant | 73 | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.